Topics
Low-grade gliomas | Treatment | Targeted therapy | Tovorafenib
Home > Publications > Topics > Low-grade gliomas > Treatment > Targeted terapy > Tovorafenib
2024
van Tilburg CM, Kilburn LB, Perreault S, Schmidt R, Azizi AA,
Cruz-Martínez O, Zápotocký M, Scheinemann K,
Meeteren AYNS, Sehested A, Opocher E, Driever PH, Avula S, Ziegler
DS, Capper D, Koch A, Sahm F, Qiu J, Tsao LP, Blackman SC, Manley
P, Milde T, Witt R, Jones DTW, Hargrave D, Witt
O.
LOGGIC/FIREFLY-2: a phase 3,
randomized trial of tovorafenib vs. chemotherapy in pediatric and
young adult patients with newly diagnosed low-grade glioma
harboring an activating RAF alteration.
BMC
Cancer. 2024 Jan 30;24(1):147. doi:
10.1186/s12885-024-11820-x. PMID:
38291372. Interventional
study
protocol.
ˍ
2026
Figueira K, Pigott LE.
Outcomes of
target therapies for pediatric BRAF V600-mutant low-grade gliomas:
A systematic review and meta-analysis.
Neurooncol
Adv. 2026 Jul 27;8(1):vdag192. doi:
10.1093/noajnl/vdag192. PMID:
42633479. ˍ